Dentons advised Immunic, Inc. on its private placement financing of up to US$400 million, including US$200 million in initial proceeds and the potential for an additional US$200 million.
The financing is expected to support the completion of Immunic’s Phase III clinical trials and its transition to a commercial organization, advancing the company’s long-term growth and strategic objectives.
Dentons was pleased to support Immunic on these transactions with a Venture Technology team led by Ilan Katz, Grant Levine, Zachary Weiss, and Madeline Hunter in New York.